__NUXT_JSONP__("/drugs/Capmatinib", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[{brand:"TABRECTA",indication:"1 INDICATIONS AND USAGE TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14)] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 )",manufacturer:"Novartis Pharmaceuticals Corporation",splSetId:"455892c3-d144-4ba8-9ab4-79cabff9876d"}],id:a,nciThesaurus:{casRegistry:"1029712-80-8",chebiId:b,chemicalFormula:b,definition:"An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.",fdaUniiCode:"TY34L4F9OZ",identifier:"C90564",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C129825","C1742","C1967"],synonyms:["2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide","CAPMATINIB",a,"INC-280","INC280","INCB 28060","INCB028060","INCB28060"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FCapmatinib",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Capmatinib","","2021-10-30T13:47:09.743Z")));